Technical Description
This technology describes the multitarget triazole-bridged cycloaryl analogues with dual cholinesterase inhibition, neuroprotective effects, and anti-amyloid β aggregation for Alzheimer’s disease treatment.
Problems Addressed
- Limited Therapeutic Options
- Ineffective Multi-Target Inhibition
- Unsuccessful Drug Trials
- Inadequate Neuroprotection
- High Disease Burden
- Absence of Novel Pharmacophores
Tech Features
- Enhanced Dual Cholinesterase Inhibition
- Efficient Aβ Aggregation Prevention
- Optimized Blood-Brain Barrier Permeability
- Advanced Neuroprotective Properties
- Multifunctional Hybrid Analogues
- Innovative Synthesis Approach
Target Audience
- Pharmaceutical & Drug Development Companies
- Biotech & Therapeutics Sector
- Neuroscience & Neurology Research Centers
- Clinical & Healthcare Institutions
- Academic & Research Institutions
Tech ID: P27-1314 TRL 4 Patent Status: Granted Available For Exclusive and Non-exclusive License
